AR049699A1 - Derivados de pirimidina - Google Patents
Derivados de pirimidinaInfo
- Publication number
- AR049699A1 AR049699A1 ARP050102606A ARP050102606A AR049699A1 AR 049699 A1 AR049699 A1 AR 049699A1 AR P050102606 A ARP050102606 A AR P050102606A AR P050102606 A ARP050102606 A AR P050102606A AR 049699 A1 AR049699 A1 AR 049699A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidinyl
- alkyl
- aryl
- benzenesulfonamide
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula (1), en la que: R1 es alquilo, cicloalquilo, cicloalquiloxi, alcoxialquilo, cicloalquilalcoxialquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, ariloxialquilo, amino o aminoalquilo; R2 es hidrogeno, alquilo o arilo; R3 es hidrogeno, alquilo o arilo; R4 es fenilo, naftilo, tiofenilo, quinolilo, piperidilo, morfolilo o tiomorfolilo, en los que fenilo, naftilo, tiofenilo, quinolilo, piperidilo, morfolilo y tiomorfolilo están opcionalmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre alquilo, cicloalquilo, halogeno, alcoxi, ciano, trifluorometilo, arilo, arilalquilo, ariloxi, oxazolilo, piridinilo, pirimidinilo, pirazolilo, imidazolilo y tiazolilo; R5 es hidrogeno, alquilo, aralquilo, cicloalquilalquilo o aminocarbonilalquilo; y sales y ésteres farmacéuticamente aceptables de los mismos; y de la están excluidas: la N-(2,6-dimetil-4-pirimidinil)-bencenosulfonamida; la 2- cloro-N-(2-metil-4-pirimidinil)-p-toluenosulfonamida; la N-(2-(dimetilamino)-6-metil-5-propil-4-pirimidinil)-bencenosulfonamida; y la 2,4,5-tricloro-N-(2,6-dimetil-4-pirimidinil)-bencenosulfonamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102999 | 2004-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049699A1 true AR049699A1 (es) | 2006-08-30 |
Family
ID=35478760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102606A AR049699A1 (es) | 2004-06-28 | 2005-06-24 | Derivados de pirimidina |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7507733B2 (es) |
| EP (1) | EP1763517B1 (es) |
| JP (1) | JP4809339B2 (es) |
| CN (1) | CN1972918B (es) |
| AR (1) | AR049699A1 (es) |
| AT (1) | ATE509011T1 (es) |
| AU (1) | AU2005256442B2 (es) |
| BR (1) | BRPI0512705A (es) |
| CA (1) | CA2571361C (es) |
| DK (1) | DK1763517T3 (es) |
| ES (1) | ES2362884T3 (es) |
| IL (1) | IL179914A0 (es) |
| MX (1) | MXPA06014892A (es) |
| MY (1) | MY143568A (es) |
| NO (1) | NO20070445L (es) |
| NZ (1) | NZ551859A (es) |
| PL (1) | PL1763517T3 (es) |
| PT (1) | PT1763517E (es) |
| RU (1) | RU2375351C2 (es) |
| TW (1) | TWI299040B (es) |
| WO (1) | WO2006000371A2 (es) |
| ZA (1) | ZA200610415B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5140577B2 (ja) * | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
| PA8713501A1 (es) * | 2006-02-07 | 2009-09-17 | Wyeth Corp | INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2046753A2 (en) * | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
| AU2009279787B2 (en) * | 2008-08-04 | 2014-05-29 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| EP2322505A4 (en) | 2008-08-29 | 2011-10-19 | Kowa Co | 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH |
| TW201022210A (en) | 2008-10-29 | 2010-06-16 | Kowa Co | 1,2-diazetidin-3-one derivatives and drugs containing same |
| NZ601547A (en) | 2010-01-25 | 2014-04-30 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2012051139A1 (en) * | 2010-10-15 | 2012-04-19 | Amgen Inc. | New uses for substituted 2-amino-thiazolones in treating alzheimer's disease |
| JPWO2012102366A1 (ja) * | 2011-01-28 | 2014-06-30 | 日本たばこ産業株式会社 | 新規ピペラジン化合物の製造方法 |
| CN103827095A (zh) | 2011-08-30 | 2014-05-28 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 |
| PH12017502049A1 (en) | 2011-08-30 | 2018-08-29 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| PE20170770A1 (es) | 2014-07-17 | 2017-07-04 | Chdi Foundation Inc | Metodos y composiciones para tratar trastornos relacionados con vih |
| WO2017160922A1 (en) | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1229413A (es) * | 1967-06-14 | 1971-04-21 | ||
| JP2744663B2 (ja) * | 1988-12-29 | 1998-04-28 | 三井化学株式会社 | ピリミジン類及びその薬学的に許容される塩類 |
| HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| TW287160B (es) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
| TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| CA2485681C (en) * | 2002-05-24 | 2012-10-16 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| BRPI0510095A (pt) * | 2004-04-20 | 2007-10-16 | Transtech Pharma Inc | tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina |
-
2005
- 2005-06-20 JP JP2007518500A patent/JP4809339B2/ja not_active Expired - Fee Related
- 2005-06-20 BR BRPI0512705-0A patent/BRPI0512705A/pt not_active IP Right Cessation
- 2005-06-20 NZ NZ551859A patent/NZ551859A/en not_active IP Right Cessation
- 2005-06-20 RU RU2007103303/04A patent/RU2375351C2/ru not_active IP Right Cessation
- 2005-06-20 MX MXPA06014892A patent/MXPA06014892A/es active IP Right Grant
- 2005-06-20 DK DK05755629.2T patent/DK1763517T3/da active
- 2005-06-20 CA CA2571361A patent/CA2571361C/en not_active Expired - Fee Related
- 2005-06-20 EP EP05755629A patent/EP1763517B1/en not_active Expired - Lifetime
- 2005-06-20 PL PL05755629T patent/PL1763517T3/pl unknown
- 2005-06-20 AT AT05755629T patent/ATE509011T1/de active
- 2005-06-20 ES ES05755629T patent/ES2362884T3/es not_active Expired - Lifetime
- 2005-06-20 PT PT05755629T patent/PT1763517E/pt unknown
- 2005-06-20 AU AU2005256442A patent/AU2005256442B2/en not_active Ceased
- 2005-06-20 CN CN2005800209571A patent/CN1972918B/zh not_active Expired - Fee Related
- 2005-06-20 WO PCT/EP2005/006649 patent/WO2006000371A2/en not_active Ceased
- 2005-06-24 AR ARP050102606A patent/AR049699A1/es unknown
- 2005-06-24 TW TW094121333A patent/TWI299040B/zh not_active IP Right Cessation
- 2005-06-27 US US11/168,031 patent/US7507733B2/en not_active Expired - Fee Related
- 2005-06-27 MY MYPI20053011A patent/MY143568A/en unknown
-
2006
- 2006-12-07 IL IL179914A patent/IL179914A0/en unknown
- 2006-12-12 ZA ZA200610415A patent/ZA200610415B/en unknown
-
2007
- 2007-01-24 NO NO20070445A patent/NO20070445L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007103303A (ru) | 2008-08-10 |
| WO2006000371A3 (en) | 2006-04-27 |
| RU2375351C2 (ru) | 2009-12-10 |
| PL1763517T3 (pl) | 2011-10-31 |
| TW200616976A (en) | 2006-06-01 |
| CA2571361A1 (en) | 2006-01-05 |
| JP4809339B2 (ja) | 2011-11-09 |
| PT1763517E (pt) | 2011-07-01 |
| NO20070445L (no) | 2007-01-24 |
| ZA200610415B (en) | 2008-06-25 |
| AU2005256442B2 (en) | 2009-02-12 |
| US7507733B2 (en) | 2009-03-24 |
| MXPA06014892A (es) | 2007-02-28 |
| HK1104553A1 (zh) | 2008-01-18 |
| TWI299040B (en) | 2008-07-21 |
| AU2005256442A1 (en) | 2006-01-05 |
| NZ551859A (en) | 2010-05-28 |
| IL179914A0 (en) | 2007-05-15 |
| EP1763517B1 (en) | 2011-05-11 |
| ES2362884T3 (es) | 2011-07-14 |
| DK1763517T3 (da) | 2011-06-06 |
| CN1972918A (zh) | 2007-05-30 |
| JP2008504321A (ja) | 2008-02-14 |
| WO2006000371A2 (en) | 2006-01-05 |
| BRPI0512705A (pt) | 2008-04-01 |
| CA2571361C (en) | 2011-07-26 |
| CN1972918B (zh) | 2010-10-13 |
| EP1763517A2 (en) | 2007-03-21 |
| US20050288308A1 (en) | 2005-12-29 |
| ATE509011T1 (de) | 2011-05-15 |
| MY143568A (en) | 2011-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049699A1 (es) | Derivados de pirimidina | |
| AR049739A1 (es) | Derivados de aril-piridina | |
| RU2201927C2 (ru) | Амидиновые соединения и фармацевтическая композиция, обладающая фактор ха ингибирующим действием | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| NO20070555L (no) | Kinazolinonderivater som parp-inhibitorer | |
| CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
| PE20081530A1 (es) | Nuevos compuestos 617 | |
| PE20060598A1 (es) | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 | |
| NO20070529L (no) | Kinazolindionderivater som parp-inhibitorer | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| BRPI0612888A8 (pt) | anilino-piridinotriazinas cíclicas | |
| TNSN05069A1 (fr) | Derives de la quinolyl propyl piperidine et leur utilisation en tant qu'agents antimicrobiens | |
| MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| NO20063129L (no) | Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer | |
| CY1112326T1 (el) | Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| WO2008111604A1 (ja) | 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| AR054688A1 (es) | Alquil-piridinas como inhibidores 11-beta de la diabetes | |
| AR066603A1 (es) | Derivados de arilamida pirimidona | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
| PE20080206A1 (es) | Derivados de aril y heteroaril-etil-acilguanidina como inhibidores de renina | |
| PE20091782A1 (es) | Derivados de sulfonamida sustituida | |
| NO20071230L (no) | Oksazolidinoner inneholdende oksindoler som antibakterielle midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |